At UT Health Austin, we believe in actively listening to patients to help patients achieve the health goals that matter most to them – in the care room and beyond. Our clinicians and staff are committed to building trust with patients by working with each patient to create an individualized care plan that addresses their unique circumstances, priorities, and beliefs.
Expectant parents who receive a diagnosis of a potentially serious fetal issue experience a range of emotions, and establishing care with a provider you trust can help improve your health outcomes. UT Health Austin fetal medicine specialist Kenneth Moise, Jr., MD, brings together a team of specialists who are prepared to listen to your health goals and help you achieve them. As Director of the Comprehensive Fetal Care Center, a clinical partnership between Dell Children’s Medical Center and UT Health Austin, Dr. Moise emphasizes the importance of family-centered care that includes care for the mother and baby before, during, and after pregnancy.
Dr. Moise diagnoses, treats, and manages the care of patients with complex and rare fetal conditions, including fetal heart anomalies, congenital diaphragmatic hernia, urinary tract abnormalities, twin-to-twin transfusion syndrome, and neural tube defects, such as spina bifida. He has developed fetal centers across the country to ensure patients and their families receive the highest level of specialized care before, during, and after delivery.
Dr. Moise is a professor in the Dell Medical School Department of Women’s Health, where he provides education and training for the next generation of fetal care providers. He also provides subspecialty training in maternal-fetal medicine for residents through the Dell Medical School Obstetrics and Gynecology Residency program.
Dr. Moise is recognized world-wide for his contributions in the fetal treatment of Rh disease, also known as hemolytic disease of the fetus and newborn (HDFN), including the development of middle cerebral artery Doppler for the non-invasive detection of fetal anemia and the use of free fetal DNA to determine the fetal RHD status. He is currently the principal investigator of an ongoing international clinical trial to evaluate the safety and efficacy of a pharmaceutical that would eliminate the need for intrauterine transfusion in HDFN treatment.